Rapid Test Ag 2019-nCoV (PROGNOSIS, Biotech, Larissa, Greece); Performance Evaluation in Hospital Setting with Real Time RT-PCR
Bibliographic Data
The Rapid Test Ag 2019-nCoV demonstrated sufficient sensitivity, excellent specificity and could be available to be used with low overall cost. Thus, it could be used as point of care test, but also for mass screening for rapid detection of infected persons (e.g., for travelers)
2019-20 coronavirus outbreak · Biology · Chromatography · Coronavirus disease 2019 (COVID-19 · Detection limit · Disease · Gene · Infectious disease (medical specialty · Nucleic acid test · Pathology · Point of care · Point-of-care testing · Polymerase chain reaction · Real-time polymerase chain reaction · Reverse transcription polymerase chain reaction · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 · Test (biology · Chemistry · Medicine · Respiratory viral infections research · SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Genetics · Immunology · Internal Medicine · Virology
| Highly cited | No |
|---|